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Abstract:  Vital dyes contain complex molecules with chromophores that stain living 
tissues and have greatly enhanced identification and removal of transparent vitreoretinal 
tissues during surgery. Several “chromovitrectomy” dyes are frequently used by 
vitreoretinal specialists, including indocyanine green, trypan blue, brilliant blue G and 
triamcinolone acetonide; other dyes are also under investigation.  Currently available 
chromovitrectomy dyes have their limitations, and of particular concern is their 
possibility for acute and chronic toxicity to the neurosensory retina and retinal 
pigmented epithelium. The potentially irreversible acute toxicity and other limitations, 
such as lack of long-term safety profiles, highlight the need for a review of the current 




















In all surgical fields, visualization of tissues and anatomic planes assumes 
paramount importance. In vitreoretinal surgery, the surgical planes may be only microns 
thick, and neighbouring nerve fiber layer tissues are susceptible to mechanical damage 
with secondary adverse visual sequelae. Thus, surgical dissection in the appropriate 
plane without traumatizing underlying retinal structures is critical. Particularly 
challenging in retinal surgery is the visualization of transparent preretinal tissues such 
as internal limiting membrane (ILM), epiretinal membrane (ERM) and the vitreous 
cortex.  Vital dyes are complex molecules containing chromophores, the structure of a 
molecule responsible color,1 that stain living tissues and have greatly enhanced 
identification and removal of transparent anatomical layers during vitreoretinal surgery.  
Currently available chromovitrectomy dyes do have their limitations. The 
properties of an ideal dye for vitreoretinal surgery include lack of toxicity to all retinal 
layers, easy application and extraction from the eye, excellent staining and contrast of 
desired tissues, no potential for phototoxicity, low cost, minimal preparation and 
existing Food and Drug Administration (FDA) approval.  Several chromovitrectomy 
dyes are frequently used by vitreoretinal specialists, including indocyanine green (ICG), 
trypan blue (TB), brilliant blue G (BBG) and triamcinolone acetonide (TA); other dyes 
are also currently under investigation. The 2017 American Society of Retinal Specialists 
(ASRS) Preferences and Trends (PAT) survey demonstrated that of United States (US) 
retina specialists survey responders, 69.0% percent preferred to use ICG to aid in ERM 
and/or ILM peeling, 9.5% preferred TA, 14.8% used BBG, 1.2 % used TB, 3.1% 
preferred no dye, and 2.4% used an unlisted dye.2 Additionally, the last decade has seen 
a trend towards more US providers utilizing ICG, despite some reports of toxicity, with 
a slight decrease in the use of TA and TB (Figure 1).2-6  
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Of particular concern with chromovitrectomy dyes is the potential for acute 
and/or chronic toxicity to the neurosensory retina and retinal pigmented epithelium 
(RPE), and the toxicity of commonly used dyes is discussed throughout this text. While 
most physicians peel the ILM during macular hole surgery due to the improvement in 
macular hole closure rates, the visual results of ILM peeling during ERM resection are 
less convincing. Despite reducing the rate of recurrence of ERMs, ILM peeling has not 
convincingly improved visual outcomes, and the recurrence rate of ERMs is already 
relatively low.7 The potential for harmful effects, varied practice patterns and other 
limitations highlight the need for a current literature review and further advancements.   
 
 
Historical perspective: Introduction of ICG-assisted ILM peeling 
Surgical repair of idiopathic macular holes has undergone significant evolution 
in the last three decades. In 1991, Kelly and Wendel published a technique for surgical 
closure, in which pars plana vitrectomy (PPV) was combined with intraocular gas 
tamponade and face down positioning. This procedure resulted in 58% macular hole 
closure rate and 42% improvement in visual acuity (VA), a tremendous improvement 
compared to observation.8 Over the ensuing decade, various modifications to this 
technique were investigated, with the goal of improving closure rates and visual 
outcomes. The technique that is currently popular involves removal of the ILM around 
the macular hole. It is hypothesized that ILM removal reduces tangential forces on the 
fovea, which act as a potential mechanism for failure of macular hole closure.  In 1997, 
Eckardt et al. published a series of 39 full-thickness macular holes that underwent ILM 
peeling during PPV, and demonstrated a notable improvement in closure rate of 92%.9  
Follow-up studies confirmed these closure rates, effectively establishing the role of ILM 
peeling in macular hole repair. By 2014, the ASRS PAT survey noted 93% of 
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responding US retinal physicians performed routine ILM peeling during macular hole 
surgery.5  
One of the technical difficulties in peeling the ILM is adequate visualization of 
this thin transparent membrane, with concern for damage to the inner retinal nerve fiber 
layer and permanent scotoma from excessive manipulation. Challenges in consistent 
visualization of ILM led investigators to evaluate ICG as a dye to stain this transparent 
layer. ICG is a water-soluble, tricarbocyanine dye with infrared absorption properties 
that was initially used as a contrast agent in radiology. Prior to its use for ILM peeling, 
ICG has been used for imaging of the choroidal circulation and was also investigated 
for staining of the anterior lens capsule in cataract surgery.10 A favorable safety profile 
for ICG was suggested by the lack of adverse effects when it was used for dye-based 
angiography, even in cases where large amounts of ICG dye leaked into or under the 
retina.11,12 For surgical use, ICG in the form of a powder must be dissolved in sterile 
water and diluted to the desired concentration. 
In 2000-2001, teams in both Japan and the US evaluated ICG-assisted ILM 
peeling in animal models, and the preliminary safety and success of these preclinical 
studies led to human trials. In humans, following PPV and PVD induction, the ICG was 
applied directly to the ILM for several minutes and was then aspirated. The staining 
provided enhanced visualization of the ILM and aided in its peeling. The resulting 
supportive publications with excellent images, along with the conceptual appeal, good 
outcomes and early lack of adverse events generated positive response within the 
vitreoretinal community.13,14  
 Over the ensuing years, various groups replicated the successful staining 
demonstrated in these original studies.15-17 However, case reports of potential toxicity 
related to ICG soon surfaced, including reports of worse visual acuity outcomes and 
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peripheral visual field defects.18-22 Retinal pigmentary changes were observed in up to 
50% in some series and reports of RPE atrophy surfaced as well.23-25 However, the 
development of RPE changes following PPV may be unrelated to the use of ICG, as the 
Vitrectomy for Macular Hole Study Group in 1997 was performed prior to the 
application of ICG or other dyes, and noted that 33% of patients developed RPE 
changes.26 In 2001, Gandorfer et al. worked on elucidating the potential reasons for 
these adverse outcomes by performing electron microscopy on excised ILMs. To their 
surprise,  microscopy revealed that, in addition to ILM removal, plasma membranes of 
Muller cells, Muller cell foot plates and other undetermined cellular debris were 
excised.18  In contrast, ILM peeling without the assistance of ICG, did not reveal 
excessive excision of non-ILM tissue.27   
While the exact mechanisms for ICG-related injury to retinal tissue remains 
controversial, studies suggest that ICG has direct toxicity to the RPE, especially if 
utilized at higher concentrations and over longer periods ofcontact during surgery. The 
hypothetical mechanisms for ICG-related RPE and neurosensory retinal damage are 
summarized in Table 1, along with suggested techniques to minimize damage.  
Conflicting rates of these adverse outcomes have been published in larger 
studies;22,28-31  variations in ICG concentration, addition of dextrose 5% in water (D5W) 
to the diluent, ICG exposure time, endoillumination time, surgeon experience and the 
degree of irrigation confound comparison of different studies.  Possibly the best 
evidence to date is a 2012 meta-analysis of both retrospective and randomized, 
prospective studies. This analysis compiled the results from twenty-two studies and 
1585 eyes, and concluded that ICG-assisted ILM peeling was associated with increased 
rates of visual field defects and worse visual acuity outcomes compared to ILM peeling 
without ICG.  In particular, the percentage of patients who improved to better than 
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20/40 was lower in those with the ICG-assisted peeling compared to the those without 
ICG (OR 0.61, 95% CI 0.43 to 0.97, p=0.033), despite similar macular hole closure 
rates. 32 Based on the potential adverse effects of ICG, there continues a search for 
alternative dyes for routine staining of the ILM. Alternatively, steps should be taken to 
minimize the concentration, exposure time and illumination during surgery.  
 
Table 1. Hypothetical mechanisms for indocyanine green (ICG)-related tissue 
damage and suggested techniques to minimize this damage.   
Hypothetical mechanisms 
for ICG-related tissue 
damage 
Suggested techniques to minimize damage 
Dose- and time-dependent 
direct toxicity to RPE33,34 
Minimize the dose (0.5mg/mL) and minimize exposure time during 
surgery.35  Copiously irrigate ICG to minimize chronic direct 
toxicity. Avoid direct injection to the macular hole or use various 
materials (ex: viscoelastic material) to create a barrier between ICG 
and RPE.36,37 
Acute and chronic 
phototoxicity38 
Minimize direct and proximal light-pipe illumination during 
surgery.39 Copiously irrigate ICG to minimize chronic phototoxicity. 
Dissolving the dye in BSS or D5W alters the absorption spectrum 
and can minimize phototoxicity.40 
More aggressive surgical 
excision41,42 
Minimize manipulation of ILM and underlying neurosensory retina. 
However, the aggressive surgical excision may in part be due to ICG 
chemically modifying the surgical plane. 
Hypo-osmotic effects 
(controversial) 33,43,44 
Utilize a physiologic osmolarity  
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BSS, balanced salt solution; D5W, 5% dextrose in water; ICG, indocyanine green; RPE, 
retinal pigment epithelium 
This table describes the hypothetical mechanisms for ICG-related retina toxicity and 
techniques to minimize potential toxicity.  
 
 
ICG has separately been investigated to facilitate epiretinal membranesurgery.  
While several studies have confirmed poor ERM staining with ICG as highlighted in 
Figure 2, the negative ICG staining of ERM accompanied by staining of adjacent ILM 
may facilitate removal of both ERM and ILM combined.45,46 Negative staining with 
ICG and other dyes, wherein the lack of staining of the tissue of interest, contrasted by 
staining of adjacent tissue, improves visualization and can aid in excision. Negative 
staining techniques have been applied to the removal of vitreous, posterior hyaloid, 
ERM and ILM.47  
Other dyes such as TB and triamcinolone, discussed later in this review, more 
favourably stain ERMs.  Finally, infracyanine green (IFCG), a biosimilar dye to ICG, 
was briefly investigated as an alternative to ICG and was hypothesized to have an 
improved safety profile due to a more physiological osmolarity as well as a lack of 
iodine.48-52 After several published investigations, alternate dyes such as trypan blue and 
brilliant blue G gained more investigative enthusiasm and IFCG is not routinely used.  
 
Brilliant Blue G 
Brilliant blue G, also known as acid blue 90 and Coomassie BBG, is a blue dye 
that non-selectively binds to most proteins and has been utilized for protein staining in 
biologic fields. The potential toxicity of ICG led investigators in Japan to evaluate the 
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safety of this dye. In 2006, Enaida et al. published a thorough evaluation of various 
doses of BBG in vitrectomized rat eyes. Following successful preclinical evaluation, 
BBG was investigated in humans as a dye for ERM and ILM peeling (Figure 3). In 
2006, Enaida et al. published the successful application of 0.25 mg/ml of BBG during 
epiretinal membrane resection and ILM peeling for macular hole repair in a small group 
of eyes. No BBG-related adverse events were noted, but peripheral visual field 
evaluation was not performed. Similarly, ERMs were well-visualized and effectively 
peeled, without documented BBG-related adverse events.  Follow-up studies confirmed 
efficacy of BBG in ILM staining, with minimal observed toxicity.53 A recent review and 
meta-analysis of 846 eyes demonstrated the superior visual outcomes of BBG compared 
to ICG for ILM peeling in macular hole surgery.54 Long-term follow-up, of an average 
of 2 years following surgery, similarly demonstrated superior visual acuity outcomes for 
BBG over ICG.55  
Limitations of BBG include the possible subjective and objective inferiority of 
ILM staining compared to ICG, lack of FDA approval, minimal staining of ERMs and 
reports of adverse events.56 Despite its possible inferior staining, as compared to ICG, 
the dye’s widespread use suggest adequate ability to aid in visualization of the ILM. 
The number of adverse events reported with BBG is fewer than with ICG.57  On 
examination of excised ILMs following the application of various dyes, BBG had 
similar findings as TB, BPB and CB, and specimens did not contain large cellular 
fragments and Muller cell end-feet as was found with ICG derived ILM specimens.58 
The clinical significance of the excision of a small amount of retinal tissue still remains 
to be elucidated. Similar to the use of ICG, greater light intensity and duration, as well 
as higher concentrations of BBG and contact time, have been demonstrated in vivo to 
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result in cell toxicity; thus, application dose and duration should be minimized during 
surgery.59   
Currently, approximately 14.8% of US providers utilize BBG for aid in ILM 
peeling.2 For surgical use, it can be purchased as a solution that is then diluted to a 
desired concentration. It is commercially available as Brilliant Peel® (Fluoron, Ulm, 
Germany) and Ocublue Plus® (Aurolab, Madurai, India). It is available in combination 
with trypan blue as Bio-Blue DUO® (Biotech Visioncare, Gujarat, India) and 
Membrane Blue-Dual® (Dutch Ophthalmic Research Center, Zuidland, Netherlands), 
and with trypan blue and lutein as Doubledyne®, Tripledyne® and Retidyne® (Kemin 
Industries, Inc., U.S.A). Overall, BBG appears to have fewer safety concerns than ICG 
but, it has slightly inferior staining properties, is not FDA approved, requires 
compounding and the long-term adverse and visual field effects have not been 
thoroughly evaluated.  
 
Triamcinolone Acetonide 
Triamcinolone acetonide (TA) is a sterile, corticosteroid, suspension that is used 
in one of two forms for vitreoretinal surgery: Non-preservative free triamcinolone 
acetonide (non-PFTA), commercially available as Kenalog® (Bristol-Myers Squibb, 
NJ) or preservative free triamcinolone acetonide (PFTA), commercially available as 
Triescence® (Alcon, Fort Worth, TX). Non-PFTA is formulated in a vehicle that 
contains 0.99% benzyl alcohol as a preservative. While its intraocular use is off-label, 
non-PFTA was the initial formulation used for intravitreal injection for macular edema 
and then used as an adjuvant during PPV.60 There are concerns about the preservative in 
non-PFTA which has produced in vitro retinal cell toxicity.  Thus, PFTA was developed 
as an alternative, and is an FDA approved corticosteroid for intraocular use. It is 
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available as a 1 mL vial with a concentration of 40 mg/mL. Advantages of PFTA 
include its FDA-approved status for intraocular use (Triescence) and the lack of 
preservatives, while non-PFTA is more cost-effective.  Currently, approximately 9.5% 
of US providers utilize TA for aid in peeling the ERM or ILM.2  
Within vitreoretinal surgery, TA can be utilized during PPV, where it adheres to 
vitreous to enhance visualization.  It facilitates visualization of vitreous cortex and the 
separation of the posterior hyaloid, tissues that can be challenging to visualize due to 
their transparency. Upon administration into the vitreous cavity, the compound becomes 
trapped within the vitreous gel, where the white steroidal crystals provide contrast with 
adjacent tissues. Since 2000, the use of TA for vitreous visualization rapidly gained 
acceptance due to this effective coating ability..61,62  
In addition to the effective staining of vitreous, TA has also been investigated 
for other surgical applications. The corticosteroid coats the ILM, possibly due to 
residual collagen fibers on the transparent tissue following hyaloid separation.63,64  As 
opposed to staining with dyes such as ICG, TA coats tissues allowing for visualization 
of peeled membranes.65 Retrospective analyses of TA application in MH repair has not 
shown toxicity to the retina or RPE, in contrast to the early ICG for macular hole 
surgery studies.55,66 Furthermore, in select studies, the visual outcomes with the use of 
TA were superior to the use of ICG.67 Additional applications include the coating of 
ILM and ERM in PVR resection.68    
With regard to safety, TA use during vitrectomy has been inconsistently 
associated with postoperative ocular hypertension.66,69 The conflicting results are likely 
due to the independent ocular hypertensive effects of PPV as well as the use of gas and 
periocular or topical corticosteroids.66,67 The rates of ocular hypertension are 
significantly lower than following intravitreal depot injection because most TA is 
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washed out during PPV. However despite irrigation, several studies have found residual 
TA on or beneath the retina. Fortunately, no local untoward effects of this residual TA 
have been demonstrated, likely due to its indolent nature and relatively short half-life in 
ocular tissue (18.6 days in nonvitrectomized eyes and 3.2 days in vitrectomized eyes), 
with the residual TA following vitrectomy typically absorbed by 8 weeks.67,70-73 Studies 
have not shown increased rates of endophthalmitis or cataract formation with the use of 
TA during PPV despite the cataractogenic and immunosuppressive nature of 
corticosteroids.66  
 Overall, TA is a useful adjuvant to coat the vitreous cortex during PPV and 
facilitate posterior hyaloid separation. Additionally, its coating ability facilitates ERM 
and preretinal membrane peeling. It does not stain ILM to the extent of the other vital 




Trypan blue (TB) is an anionic, hydrophilic azo dye. After favourable safety 
data following its use in the anterior segment as an anterior capsular stain, it has been 
evaluated in vitreoretinal surgery to stain epiretinal membranes and the ILM. 
Favourable preclinical safety studies led to the first investigation of TB as an aid 
to ERM peeling in proliferative vitreoretinopathy.74 Shortly thereafter, TB dye 
demonstrated efficacy staining the ILM during macular hole surgery.75 Numerous 
studies indicate that TB stains both the ERM and ILM,75-80 but other authors contend 
that TB does not effectively stain the ILM.81,82 
Some safety concerns have arisen although not to a similar magnitude as with 
ICG. Similarly to ICG studies and the natural history following macular hole surgery 
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without the use of vital dyes, several publications have noted development of RPE 
atrophy following macular hole surgery using adjuvant TB.83,84 Histopathologic studies 
evaluating TB-surgically removed ILM specimens show variable amounts and sizes of 
glial elements, although typically less fragments than with ICG. 58,85,86 This variability 
in results may be related to differences in aggressiveness of surgical excision and lack 
of standardization in evaluation of surgical specimens. Regardless, the clinical 
relevance of these neural elements on excision remains controversial, as the effect of 
excising non-ILM tissue during membrane peel has not been consistently demonstrated 
to have functional sequelae. For example, Li et al. found that despite removal of the 
neural elements with membranes, patients still had appropriate visual outcomes.85 
A prospective, randomized trial by Haritoglou suggested an acceptable safety 
profile for TB without the visual field defects, RPE changes or suboptimal visual acuity 
outcomes that were observed after ICG-assisted ILM peeling. 87  In a direct prospective, 
non-randomized comparison of IFCG and TB-assisted peeling of the ILM, TB had 
better central visual field results.51 In contrast, a prospective, randomized study, 
investigating a larger number of patients, found no difference in visual field or visual 
acuity outcomes between ICG- and TB-assisted ILM peeling in macular holes.88 These 
two studies provide the best quality evidence comparing TB with other dyes.  Overall, 
they are suggestive of good central visual acuity and peripheral visual field outcomes 
with the use of TB, with possible but not definitive superiority over ICG.  
 Trypan blue (TB) was approved by the FDA in 2009 for epiretinal membrane 
removal and is available as MembraneBlue 0.15%® (Dutch Ophthalmic USA). Of note 
is that the TB concentration approved for vitreoretinal surgery is 0.15% and differs from 
that of VisionBlue 0.06% which is approved for staining of the anterior lens capsule. 
Despite FDA approval, only 1% of US providers utilize TB for ERM and/or ILM 
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removal as per the 2017 ASRS PAT survey.2 Despite possibly fewer adverse events 
compared to ICG as well as FDA approval, the lack of popularity of TB stems from 
inferior ILM staining compared to the alternative dyes which narrows its applications.   
 
Investigational Dyes 
Numerous dyes have been proposed as alternatives to those currently used, with the 
ultimate goals of minimizing toxicity and maximizing visualization at minimal cost. 
Since 2004, most investigational dyes haven’t advanced past preclinical trials and a few 
human case series, including Congo Red,89 Chicago Blue,90-92 E68,91,93 Evans Blue,89,94-
96 Fast Green,89,94-97 Fluorometholone acetate,98 Indigo Carmine,96 Light Green,89 
Methyl Violet,89,99,100 Methylene Blue,89,94 Orangell,99 Patent Blue V,92,101-106 
Rhodulinblua-basic 3,90,99 Rhodamine 6G,90,107 Sudan Black,89 Toluidine Blue89 and  
Trisodium.99  
Other dyes have been investigated to a greater degree, either historically or 
currently. Bromophenol Blue underwent extensive preclinical evaluation 95,97,108 and the 
blue dye results in moderate staining of ERM, ILM and vitreous.89,109  Despite in vitro 
suggestion of delayed toxicity,110 the dye has been investigated in humans without 
evident toxicity,58,111 and is commercially available at a concentration of 1.3 mg/ml with 
BBG as Brilliant Peel Dual Dye® (Fluoron, Ulm, Germany).  
Infracyanine green, was a promising alternative to ICG due to a physiologic 
osmolarity, hypothetically less cytotoxicity due to a lack of iodine, and less 
phototoxicity due to a higher peak wavelength absorption spectrum.40 In vitro studies 
supported this hypothesis and demonstrated less cytotoxicity to cultured RPE and retinal 
ganglion cells in comparison to BBG, ICG And bromophenol blue.108  Animal studies112 
and subsequently human trials suggested good visualization of ILM without obvious 
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toxicity.48,50,113 Further investigation of this dye has been surprisingly limited, with the 
last publication in 2013.95 The reasons for the possible decline of investigative fervour 
include modifications to minimize the toxicity of ICG, the regulatory approval of other 
dyes and experience suggestive of better outcomes with the use of other dyes (personal 
communication with investigator, unpublished data).   
  Lutein is a yellow-orange dye that is analogous to TA in that it coats 
intraocular tissues, in contrast to true staining. Lutein highlights the vitreous well but 
only coats ILM and ERM mildly. However, when combined with other dyes it 
hypothetically reduces cytotoxicity. The dye appears safe in preclinical114,115 and human 
studies116 and is commercially available for viretoretinal use as Retidyne®, Retidyne 
Plus® and Vitreodyne® (Kemin Industries, Inc., U.S.A).  
Acai fruit is the most promising of a group of naturally occurring dyes that have 
recently been investigated.117,118 It is a purple-colored anthocyanin dye that 
preferentially stains the ILM and recently underwent human trial (Clinicaltrials.gov: 
NCT02691429) with the results yet to be published.  
The introduction of Acid Violet to the market provides a cautionary tale. 
Preclinical evaluation suggested lack of toxicity at concentrations up to 0.125 mg/ml, 
119,120 and some concern for phototoxicity.92  Ala Medics introduced Ala Purple to the 
market at a concentration of 1.5 mg/ml. Shortly thereafter, several publications 
suggesting the dye not be used due to the toxicity at commercially available 
concentrations,121-123 and the company pulled the product from the market.  Subsequent 
in vitro studies further supported the toxicity profile of Acid Violet.124  
If dyes pass preclinical evaluation, careful evaluation in humans is required with 
focus on visual fields, retinal nerve fiber layer evaluation in addition to the traditional 
structural OCT analysis of the vitreomacular interface. For broad acceptance and 
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application, novel dyes have a major hurdle to demonstrate an interval improvement in 
staining and safety over those currently available. However, if less expensive to produce 
and distribute, they may only need to demonstrate similar safety and efficacy to become 
established in the market. A paucity of studies exists directly comparing commonly 
used dyes or comparing to ELM removal or macular hole surgery without the use of 
dye. Factors to evaluate include long term visual field and OCT retinal nerve fiber layer 
outcomes, and standard outcomes including macular hole closure rate, epiretinal 
membrane recurrence, visual acuity, macular OCT changes and development of RPE 





 Vital dyes are used to facilitate excision of transparent intraocular tissues. A 
comparison of commonly used dyes is presented in Table 2. TA is an excellent option to 
stain residual vitreous and the posterior hyaloid. TA can delineate ERM and facilitate 
removal. However, it is inferior to stain ILM compared to other options. ICG is broadly 
used in vitreoretinal surgery, but concerns exist about ICG toxicity to the RPE and 
neurosensory retina with potential visual sequelae. It is unclear whether techniques to 
minimize ICG exposure, including limiting duration of contact, minimizing 
concentration, utilizing D5W as a solvent, avoidance of application to the macular hole 
and thorough irrigation following application are able to completely eliminate potential 
for toxicity . New dyes such as BBG and novel dyes under development, may ultimately 
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Figure 1. US retina specialist ILM/ERM removal dye preference over time. The 
data, obtained from annual ASRS preference and trends surveys, demonstrates an 
increasing popularity of ICG for ILM and/or ERM peeling over the last decade, and a 
trends towards a decrease in the use of TA and TB. BBG, brilliant blue; ERM, epiretinal 
membrane; ICG, indocyanine green; ILM, internal limiting membrane; TA, 
triamcinolone acetonide; TB, trypan blue. The data for this graph was obtained and used 
in this manuscript with permission from the ASRS. ASRS, American Society of Retina 
Specialists; BBG, Brilliant Blue G; ERM, epiretinal membrane; ICG, indocyanine 
green; ILM, internal limiting membrane; TB, trypan blue; US, United States.  
 
Figure 2: Indocyanine green staining of epiretinal membrane (ERM) and internal 
limiting membrane (ILM). In image plane A, the poor staining of ERM is 
demonstrated by the translucent ERM tissue visualized over the contrasting macular 
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hole (white arrow). In contrast, in image B, the excellent staining of ILM is readily 
visualized (black arrow). Photographs courtesy of Dr. Caroline Baumal.  
 
Figure 3. Brilliant Blue G (BBG) staining of the internal limiting membrane (ILM) 
in idiopathic macular hole repair. The blue staining of the ILM with BBG provides 
excellent contrast with the underlying neurosensory retina and surrounding ILM. 
Photograph courtesy of Dr. Thomas Ciulla. 
Table 3. Comparison of various dyes, their ability to stain transparent ocular tissues and 








Indocyanine green +++ + + +++ 
Trypan Blue  + +++ + + 
Triamcinolone Acetonide + + +++ + 
Brilliant Blue G ++ + + + 
This table provides a comparison of various dyes in their ability to stain transparent ocular 
tissues and safety concerns.  ILM, internal limiting membrane; ERM epiretinal membrane; +, 
minimal; ++, moderate; +++, maximal. 
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Figure 2: Indocyanine green staining of epiretinal membrane (ERM) and internal limiting 
membrane (ILM).  
 
Figure 3. Brilliant Blue G (BBG) staining of the internal limiting membrane (ILM) in 
idiopathic macular hole repair. 
 
